

# Helen Blair Simpson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11893456/publications.pdf>

Version: 2024-02-01

65  
papers

3,174  
citations

172457

29  
h-index

155660

55  
g-index

67  
all docs

67  
docs citations

67  
times ranked

3435  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized, Controlled Trial of Cognitive-Behavioral Therapy for Augmenting Pharmacotherapy in Obsessive-Compulsive Disorder. <i>American Journal of Psychiatry</i> , 2008, 165, 621-630.	7.2	239
2	Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. <i>World Psychiatry</i> , 2016, 15, 80-81.	10.4	228
3	Cognitive-Behavioral Therapy vs Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder. <i>JAMA Psychiatry</i> , 2013, 70, 1190.	11.0	205
4	Response Versus Remission in Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 269-276.	2.2	196
5	Practice guideline for the treatment of patients with obsessive-compulsive disorder. <i>American Journal of Psychiatry</i> , 2007, 164, 5-53.	7.2	181
6	Patient adherence predicts outcome from cognitive behavioral therapy in obsessive-compulsive disorder.. <i>Journal of Consulting and Clinical Psychology</i> , 2011, 79, 247-252.	2.0	176
7	Treatment Response, Symptom Remission, and Wellness in Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 685-690.	2.2	166
8	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. <i>JAMA Psychiatry</i> , 2021, 78, 47.	11.0	136
9	Can delay discounting deliver on the promise of RDoC?. <i>Psychological Medicine</i> , 2019, 49, 190-199.	4.5	117
10	Treatment of Obsessive-Compulsive Disorder by U.S. Psychiatrists. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 946-951.	2.2	87
11	Are there reliable neuropsychological deficits in obsessive-compulsive disorder?. <i>Journal of Psychiatric Research</i> , 2006, 40, 247-257.	3.1	84
12	Challenges using motivational interviewing as an adjunct to exposure therapy for obsessive-compulsive disorder. <i>Behaviour Research and Therapy</i> , 2010, 48, 941-948.	3.1	70
13	Abnormal hippocampal structure and function in clinical anxiety and comorbid depression. <i>Hippocampus</i> , 2016, 26, 545-553.	1.9	69
14	Acceptability, Feasibility, and Effectiveness of Internet-Based Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder in New York. <i>Behavior Therapy</i> , 2018, 49, 631-641.	2.4	55
15	Development of a Patient Adherence Scale for Exposure and Response Prevention Therapy. <i>Behavior Therapy</i> , 2010, 41, 30-37.	2.4	54
16	Adding Motivational Interviewing to Exposure and Ritual Prevention for Obsessive-Compulsive Disorder: An Open Pilot Trial. <i>Cognitive Behaviour Therapy</i> , 2008, 37, 38-49.	3.5	48
17	Can Exposure-Based CBT Extend the Effects of Intravenous Ketamine in Obsessive-Compulsive Disorder?. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 408-409.	2.2	48
18	Rapid Resolution of Obsessions After an Infusion of Intravenous Ketamine in a Patient With Treatment-Resistant Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 567-569.	2.2	46

#	ARTICLE	IF	CITATIONS
19	Predictors of Patient Adherence to Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder. <i>Psychotherapy and Psychosomatics</i> , 2012, 81, 124-126.	8.8	46
20	Prevalence of Hoarding Disorder in Individuals at Potential Risk of Eviction in New York City. <i>Journal of Nervous and Mental Disease</i> , 2012, 200, 91-94.	1.0	42
21	Does Extended Release Methylphenidate Help Adults With Hoarding Disorder?. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 444-447.	1.4	41
22	Standard criteria for relapse are needed in obsessive-compulsive disorder. <i>Depression and Anxiety</i> , 2005, 21, 1-8.	4.1	40
23	Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention. <i>Behaviour Research and Therapy</i> , 2015, 68, 76-81.	3.1	39
24	Patient Adherence to Cognitive-Behavioral Therapy Predicts Long-Term Outcome in Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1265-1266.	2.2	39
25	Patient Preferences for Obsessive-Compulsive Disorder Treatment. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1434-1439.	2.2	38
26	Serotonin 2A Receptors in Obsessive-Compulsive Disorder: A Positron Emission Tomography Study with [11C]MDL 100907. <i>Biological Psychiatry</i> , 2011, 70, 897-904.	1.3	37
27	Delusional versus nondelusional body dysmorphic disorder: recommendations for DSM-5. <i>CNS Spectrums</i> , 2014, 19, 10-20.	1.2	37
28	Using Motivational Interviewing to Enhance Treatment Outcome in People With Obsessive-Compulsive Disorder. <i>Cognitive and Behavioral Practice</i> , 2011, 18, 28-37.	1.5	35
29	Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study. <i>Depression and Anxiety</i> , 2020, 37, 801-811.	4.1	34
30	White matter microstructure and its relation to clinical features of obsessive-compulsive disorder: findings from the ENIGMA OCD Working Group. <i>Translational Psychiatry</i> , 2021, 11, 173.	4.8	33
31	To Do or Not to Do? Task Control Deficit in Obsessive-Compulsive Disorder. <i>Behavior Therapy</i> , 2017, 48, 603-613.	2.4	27
32	Cannabinoid Augmentation of Exposure-Based Psychotherapy for Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 207-210.	1.4	26
33	Diagnosis and Treatment of a Patient With Both Psychotic and Obsessive-Compulsive Symptoms. <i>American Journal of Psychiatry</i> , 2010, 167, 754-761.	7.2	24
34	Six-Month Outcomes From a Randomized Trial Augmenting Serotonin Reuptake Inhibitors With Exposure and Response Prevention or Risperidone in Adults With Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 440-446.	2.2	24
35	Six-Month Follow-Up of a Randomized Controlled Trial Augmenting Serotonin Reuptake Inhibitor Treatment With Exposure and Ritual Prevention for Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 464-469.	2.2	24
36	Cognitive Mediation of Symptom Change in Exposure and Response Prevention for Obsessive-Compulsive Disorder. <i>Behavior Therapy</i> , 2016, 47, 474-486.	2.4	23

#	ARTICLE	IF	CITATIONS
37	Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept. <i>American Journal of Psychiatry</i> , 2016, 173, 1239-1241.	7.2	20
38	Statistical choices can affect inferences about treatment efficacy: A case study from obsessive-compulsive disorder research. <i>Journal of Psychiatric Research</i> , 2008, 42, 631-638.	3.1	19
39	The thalamus and its subnuclei—a gateway to obsessive-compulsive disorder. <i>Translational Psychiatry</i> , 2022, 12, 70.	4.8	19
40	Obsessive-compulsive disorder for ICD-11: proposed changes to the diagnostic guidelines and specifiers. <i>Revista Brasileira De Psiquiatria</i> , 2014, 36, 3-13.	1.7	18
41	THE RDOC PROJECT: A NEW PARADIGM FOR INVESTIGATING THE PATHOPHYSIOLOGY OF ANXIETY. <i>Depression and Anxiety</i> , 2012, 29, 251-252.	4.1	17
42	Impaired generalization of reward but not loss in obsessive-compulsive disorder. <i>Depression and Anxiety</i> , 2019, 36, 121-129.	4.1	17
43	Exposure and Response Prevention Helps Adults With Obsessive-Compulsive Disorder Who Do Not Respond to Pharmacological Augmentation Strategies. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 1653-1657.	2.2	16
44	Assessment of glutamate in striatal subregions in obsessive-compulsive disorder with proton magnetic resonance spectroscopy. <i>Psychiatry Research - Neuroimaging</i> , 2015, 232, 65-70.	1.8	16
45	Prevalence and Correlates of Difficulty Discarding. <i>Journal of Nervous and Mental Disease</i> , 2013, 201, 795-801.	1.0	14
46	Acceptability of treatments and services for individuals with hoarding behaviors. <i>Journal of Obsessive-Compulsive and Related Disorders</i> , 2016, 11, 1-8.	1.5	14
47	Pharmacological Treatment of Obsessive-Compulsive Disorder. <i>Current Topics in Behavioral Neurosciences</i> , 2009, 2, 527-543.	1.7	13
48	Heterogeneity in Fear Processing across and within Anxiety, Eating, and Compulsive Disorders. <i>Journal of Affective Disorders</i> , 2020, 275, 329-338.	4.1	13
49	Toward identifying reproducible brain signatures of obsessive-compulsive profiles: rationale and methods for a new global initiative. <i>BMC Psychiatry</i> , 2020, 20, 68.	2.6	13
50	Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 466-467.	2.2	13
51	Treatment of Obsessive-Compulsive Disorder in a Nationwide Survey of Office-Based Physician Practice. <i>Psychiatric Services</i> , 2014, 65, 681-684.	2.0	12
52	Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation. <i>JAMA Psychiatry</i> , 2022, 79, 193.	11.0	12
53	What underlies the effect of sleep disruption? The role of alertness in obsessive-compulsive disorder (OCD). <i>Journal of Behavior Therapy and Experimental Psychiatry</i> , 2017, 57, 212-213.	1.2	8
54	Patient Preferences and Acceptability of Evidence-Based and Novel Treatments for Obsessive-Compulsive Disorder. <i>Psychiatric Services</i> , 2017, 68, 250-257.	2.0	8

#	ARTICLE	IF	CITATIONS
55	Cutting-edge genetics in obsessive-compulsive disorder. Faculty Reviews, 2020, 9, 30.	3.9	8
56	Latency to treatment seeking in patients with obsessive-compulsive disorder: Results from a large multicenter clinical sample. Psychiatry Research, 2022, 312, 114567.	3.3	8
57	Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention. Psychotherapy and Psychosomatics, 2016, 85, 314-316.	8.8	4
58	Effects of Rapastinel (Formerly GLYX-13) on Serum Brain-Derived Neurotrophic Factor in Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2018, 79, 17111824.	2.2	4
59	Exploring Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Extinction Learning-Based Treatment Outcome in Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, 2019, 39, 91-93.	1.4	3
60	Pilot Study Evaluating Critical Time Intervention for Individuals With Hoarding Disorder at Risk for Eviction. Psychiatric Services, 2020, 71, 405-408.	2.0	3
61	Evidence for trial-by-trial dynamic adjustment of task control in unmedicated adults with OCD. Behaviour Research and Therapy, 2020, 126, 103572.	3.1	2
62	Innovations in the Delivery of Exposure and Response Prevention for Obsessive-Compulsive Disorder. Current Topics in Behavioral Neurosciences, 2021, 49, 301-329.	1.7	2
63	Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research. Frontiers in Psychiatry, 2021, 12, 626150.	2.6	1
64	Subcortical shape in pediatric and adult obsessive-compulsive disorder. Depression and Anxiety, 2022, 39, 504-514.	4.1	1
65	Protocol for a Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD (PROCEED). Frontiers in Psychiatry, 2022, 13, .	2.6	0